

Table S5: Age-standardized one- and three-year net survival (%) and corresponding 95% confidence limits from oesophageal cancer by histological subtype, jurisdiction and period of diagnosis

Country/ Jurisdiction	Period of diagnosis	1-year survival (95% CI)				3-year survival (95% CI)				
		AC		SCC		AC		SCC		
Australia	NSW	1995-1999	40.0	(35.7,44.3)	47.7	(44.1,51.2)	20.0	(16.6,23.7)	25.4	(22.0,28.9)
		2000-2004	42.9	(39.2,46.5)	41.3	(37.6,45.0)	21.8	(18.7,25.0)	22.1	(18.9,25.4)
		2005-2009	47.1	(43.9,50.2)	44.3	(40.3,48.2)	24.0	(21.3,26.8)	21.5	(18.3,24.8)
		2010-2014	52.3	(48.2,56.2)	49.4	(45.0,53.6)	27.5	(23.7,31.4)	24.5	(20.9,28.3)
	VIC	1995-1999	44.4	(39.7,48.9)	44.5	(39.7,49.2)	22.5	(18.6,26.6)	21.9	(18.0,25.9)
		2000-2004	46.4	(42.3,50.4)	51.3	(46.7,55.7)	20.0	(16.7,23.5)	28.6	(24.6,32.7)
		2005-2009	52.4	(48.7,56.0)	48.7	(43.5,53.7)	24.1	(20.9,27.4)	24.5	(20.3,29.0)
		2010-2014	54.0	(49.8,58.1)	60.5	(55.8,64.9)	31.4	(27.6,35.3)	40.6	(36.3,45.0)
	WA	1995-1999	43.8	(35.6,51.8)	42.7	(35.6,49.6)	20.2	(14.1,27.0)	21.9	(16.2,28.2)
		2000-2004	46.2	(39.8,52.3)	43.0	(35.7,50.0)	21.6	(16.5,27.2)	17.2	(12.0,23.2)
		2005-2009	55.3	(49.5,60.8)	51.9	(43.3,59.8)	25.1	(20.1,30.4)	23.8	(17.8,30.2)
		2010-2014	58.2	(51.6,64.3)	57.1	(48.9,64.5)	30.2	(24.5,36.1)	34.8	(27.5,42.2)
Canada	AB	1995-1999	46.2	(37.7,54.3)	29.2	(21.9,36.8)	20.4	(14.1,27.5)	11.0	(6.9,16.3)
		2000-2004	37.4	(30.6,44.1)	38.0	(31.3,44.7)	17.0	(12.2,22.4)	19.3	(13.9,25.3)
		2005-2009	42.2	(37.2,47.1)	33.8	(27.6,40.1)	15.2	(11.7,19.1)	12.6	(8.4,17.6)
		2010-2014	41.5	(36.4,46.5)	45.3	(37.1,53.1)	19.8	(15.9,23.9)	25.9	(19.2,33.1)
	BC	1995-1999	38.2	(33.3,43.1)	37.4	(32.1,42.7)	13.4	(10.1,17.2)	16.5	(12.9,20.6)
		2000-2004	39.0	(34.6,43.3)	42.1	(37.2,46.9)	16.3	(13.1,19.8)	18.3	(14.2,22.8)
		2005-2009	45.3	(41.0,49.4)	42.6	(36.5,48.6)	20.9	(17.5,24.5)	22.9	(18.5,27.5)
		2010-2014	47.6	(43.1,52.0)	48.2	(42.8,53.4)	21.0	(17.0,25.3)	24.3	(19.2,29.6)
	MB	1995-1999	35.3	(23.1,47.8)	43.8	(33.7,53.4)	11.3	(4.8,20.9)	12.9	(7.1,20.5)
		2000-2004	35.2	(25.4,45.1)	34.2	(24.2,44.4)	14.6	(8.1,23.1)	8.8	(3.5,17.0)
		2005-2009	41.2	(32.6,49.5)	39.7	(27.5,51.6)	16.0	(10.1,23.2)	11.0	(4.9,19.9)
		2010-2014	44.1	(34.9,52.9)	37.9	(26.2,49.6)	22.0	(13.5,32.0)	10.5	(4.3,20.1)
NB	1995-1999	27.8	(16.5,40.2)	35.3	(24.7,45.9)	7.7	(2.4,17.3)	17.6	(9.6,27.6)	
	2000-2004	38.5	(28.4,48.5)	45.2	(31.7,57.7)	16.1	(9.7,23.9)	15.8	(6.9,27.9)	
	2005-2009	41.1	(32.1,49.8)	39.3	(25.7,52.6)	11.8	(6.4,18.9)	23.8	(13.2,36.2)	
	2010-2014	51.7	(40.5,61.9)	57.7	(39.1,72.4)	16.1	(9.1,24.8)	31.7	(15.6,49.1)	

AC, Adenocarcinoma; SCC, Squamous cell carcinoma; NSW, New South Wales; VIC, Victoria; WA, Western Australia; AB, Alberta; BC, British Columbia; MB, Manitoba; NB, New Brunswick; NS, Nova Scotia; ON, Ontario; PE, Prince Edward Island; SK, Saskatchewan; ENG, England; NIR, Northern Ireland; SCO, Scotland; WAL, Wales.

Table S2 continued: Age-standardized one- and three-year net survival (%) and corresponding 95% confidence limits from oesophageal cancer by histological subtype, jurisdiction and period of diagnosis

Country/ Jurisdiction	Period of diagnosis	1-year survival (95% CI)				3-year survival (95% CI)			
		AC		SCC		AC		SCC	
NS	1995-1999	35.3	(24.9,45.9)	38.6	(27.7,49.4)	13.9	(7.2,22.7)	14.6	(7.7,23.7)
	2000-2004	32.7	(24.6,41.1)	35.5	(24.4,46.8)	14.2	(8.7,21.0)	15.4	(8.0,25.1)
	2005-2009	42.9	(35.6,50.0)	42.5	(29.5,55.0)	15.9	(10.4,22.5)	23.0	(13.0,34.7)
	2010-2014	50.3	(42.3,57.8)	23.6	(13.1,35.9)	23.4	(16.6,30.9)	12.9	(5.8,23.0)
ON	1995-1999	41.6	(38.4,44.7)	42.2	(39.0,45.3)	16.9	(14.5,19.4)	19.9	(17.4,22.6)
	2000-2004	46.1	(43.3,48.9)	42.9	(39.7,46.0)	19.7	(17.4,22.0)	20.2	(17.6,23.0)
	2005-2009	42.5	(40.0,45.0)	44.7	(41.6,47.8)	19.5	(17.5,21.5)	24.1	(21.1,27.2)
	2010-2014	47.7	(44.8,50.6)	42.5	(38.6,46.3)	22.7	(20.1,25.3)	20.7	(17.5,24.1)
PE	1995-1999	16.6	(3.7,37.7)	35.5	(11.8,60.5)			13.0	(1.2,39.1)
	2000-2004	38.5	(15.7,61.1)	18.1	(2.8,44.3)	25.1	(8.1,46.8)	18.7	(2.8,45.5)
	2005-2009	23.5	(9.3,41.3)	50.3	(19.1,75.2)	18.2	(6.3,35.2)	13.5	(1.6,38.2)
	2010-2014	36.1	(20.8,51.6)	52.2	(16.5,79.1)	23.4	(11.7,37.5)	9.9	(0.2,42.4)
SK	1995-1999	26.0	(17.2,35.6)	32.7	(23.5,42.2)	13.5	(7.1,22.0)	7.4	(2.7,15.6)
	2000-2004	31.3	(22.0,41.1)	31.3	(20.7,42.5)	11.2	(5.5,19.3)	13.7	(7.2,22.3)
	2005-2009	37.9	(28.3,47.3)	32.4	(21.6,43.6)	14.7	(8.8,22.0)	13.8	(6.5,23.7)
	2010-2014	53.8	(43.8,62.8)	29.4	(15.9,44.1)	17.0	(8.5,28.0)	11.4	(4.0,23.1)
ENG	1995-1999	34.6	(33.6,35.5)	31.2	(30.1,32.2)	12.5	(11.8,13.2)	12.2	(11.4,13.0)
	2000-2004	41.0	(40.1,41.8)	36.5	(35.4,37.6)	16.3	(15.6,16.9)	15.5	(14.7,16.4)
	2005-2009	45.9	(45.1,46.7)	39.9	(38.8,40.9)	19.7	(19.1,20.4)	18.1	(17.2,19.0)
	2010-2014	50.7	(49.8,51.6)	43.8	(42.5,45.1)	23.0	(22.3,23.8)	20.6	(19.5,21.7)
NI	1995-1999	42.2	(36.7,47.6)	32.4	(25.8,39.1)	16.3	(12.2,20.9)	13.6	(8.9,19.4)
	2000-2004	36.7	(31.4,42.0)	34.8	(28.1,41.5)	15.5	(11.5,20.0)	17.1	(11.9,23.1)
	2005-2009	51.0	(46.2,55.5)	35.8	(29.2,42.4)	26.1	(21.9,30.5)	18.2	(13.4,23.7)
	2010-2014	54.7	(49.5,59.5)	43.6	(36.1,50.9)	28.2	(23.6,33.0)	22.4	(15.5,30.2)
SCO	1995-1999	35.9	(33.6,38.3)	29.7	(27.2,32.3)	14.1	(12.3,16.0)	11.7	(10.0,13.6)
	2000-2004	42.5	(40.1,44.8)	34.5	(32.0,37.0)	15.9	(14.1,17.8)	13.0	(11.0,15.2)
	2005-2009	45.7	(43.3,48.0)	39.0	(35.8,42.1)	17.8	(16.0,19.7)	16.3	(13.8,18.9)
	2010-2014	50.1	(47.5,52.6)	40.3	(37.0,43.5)	21.1	(18.8,23.5)	16.7	(14.1,19.5)
WAL	1995-1999	35.3	(31.4,39.1)	30.3	(26.3,34.4)	13.1	(10.5,15.9)	15.4	(12.4,18.8)
	2000-2004	42.0	(38.8,45.3)	35.9	(32.0,39.9)	18.1	(15.6,20.8)	14.8	(12.0,17.9)
	2005-2009	45.3	(42.1,48.5)	38.0	(33.6,42.3)	17.0	(14.7,19.5)	15.2	(12.1,18.6)
	2010-2014	48.9	(45.1,52.6)	45.7	(40.4,50.9)	20.6	(17.5,23.9)	20.9	(16.3,25.8)

AC, Adenocarcinoma; SCC, Squamous cell carcinoma; NSW, New South Wales; VIC, Victoria; WA, Western Australia; AB, Alberta; BC, British Columbia; MB, Manitoba; NB, New Brunswick; NS, Nova Scotia; ON, Ontario; PE, Prince Edward Island; SK, Saskatchewan; ENG, England; NIR, Northern Ireland; SCO, Scotland; WAL, Wales.